A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Assessing new blood cells growth after transplant using cord blood units that do not meet FDA guidelines but meet NMDP guidelines
Summary
- Location
- at UC Davis UCLA UCSD UCSF
- Dates
- study started
- Principal Investigator
- by Edward Ball, MD (ucsd)Gary Schiller, MD (ucla)Mark Walters, MD (ucsf)Thomas Martin, MD (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientists at UC Health
- Edward Ball, MD (ucsd)
Dr. Ball’s research focuses on the development of monoclonal antibody (mAb)-targeted immunotherapy and its translation to the treatment of patients with malignancy. His lab produced mAbs to myeloid-associated antigens expressed on myeloid leukemia cells. - Gary Schiller, MD (ucla)
Professor-in-Residence, Medicine. Authored (or co-authored) 74 research publications. - Mark Walters, MD (ucsf)
The over-arching goal of my research career has been to develop and expand curative therapies for hemoglobin disorders in particular and non-malignant hematopoietic disorders more broadly. I have focused on genome editing approaches most recently, which rely upon modification of autologous hematopoietic cells to elicit a curative effect. - Thomas Martin, MD (ucsf)
Professor, Medicine. Authored (or co-authored) 49 research publications.
Details
- Status
- accepting new patients
- Start Date
- Sponsor
- Center for International Blood and Marrow Transplant Research
- ID
- NCT01351545
- Study Type
- Observational
- Last Updated